BOUCHERVILLE, QC, Oct. 24,
2024 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL)
("LSL Pharma" or the "Corporation"), an integrated
Canadian-based pharmaceutical company, reports that it will make on
October 31, 2024, the first interest
payment (the "Interest Payment") on its outstanding
Unsecured Redeemable Debentures (the "Debentures")
listed on the TSXV under symbol "LSL.DB". The Corporation will pay
to each Debenture holder an amount of $113.025 per $1,000
principal amount of Debentures which represents accrued interest
payable from November 1, 2023, to
October 31, 2024.
The Debentures which may be redeemed by the Corporation, have a
maturity date of October 31, 2028
(the "Maturity Date "), and accrue interest at the rate of
11% per annum (from October 31, 2024
to but excluding April 30, 2025,
subject to adjustments thereafter) payable semi-annually on the
last day of April and October of each year with the next interest
payment to take place on April 30,
2025. At the holders' option, the Debentures may be
converted into Class A shares of the Corporation at any time and
from time to time, up to the Maturity Date, at a conversion price
of $0.70 per Class A share.
For additional details regarding the Debentures, please refer to
the Debenture Indenture dated November 1,
2023, which is available under LSL Pharma's issuer profile
on www.sedarplus.ca.
About LSL Pharma Group Inc.
LSL Pharma Group Inc. is an integrated Canadian-based
pharmaceutical company specializing in the development,
manufacturing, and commercialization of high-quality sterile
ophthalmic pharmaceuticals, as well as natural health products in
solid and liquid dosage forms. For further information, please
visit our website at www.groupelslpharma.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Groupe LSL PHARMA INC.